Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: Results from the AIR registry

Rheumatology

Volumn 50, Issue 12, 2011, Pages 2283-2289

  Couderc, Marion ^a   Gottenberg, Jacques Eric ^b   Mariette, Xavier ^c   Hachulla, Eric ^d   Sibilia, Jean ^b   Fain, Olivier ^e   Hot, Arnaud ^f   Dougados, Maxime ^g   Euller Ziegler, Liana ^h   Bourgeois, Pierre ⁱ   Larroche, Claire ^j   Tournadre, Anne ^a   Amoura, Zahir ⁱ   Mazières, Bernard ^k   Arlet, Philippe ^k   De Bandt, Michel ^l   Schaeverbeke, Thierry ^m   Soubrier, Martin ^a  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^c BICÊTRE HOSPITAL   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e HÔPITAL JEAN VERDIER   (France)

^f HOSPICES CIVILS DE LYON   (France)

^g Hôpital Ballanger ^*  (France)

^h UNIVERSITY HOSPITAL OF NICE   (France)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^j AVICENNE HOSPITAL   (France)

^k CHU PURPAN   (France)

^l Rheumatology Department   (France)

^m HÔPITAL PELLEGRIN   (France)

more..

Author keywords

Adverse event; Efficacy; Inflammatory myopathy; Rituximab; Tolerance

Indexed keywords

ANTIHISTAMINIC AGENT; AZATHIOPRINE; CREATINE KINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; IMMUNOGLOBULIN G; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PARACETAMOL; RITUXIMAB;

ADULT; AGED; ANTISYNTHETASE SYNDROME; ARTICLE; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DERMATOMYOSITIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MONOTHERAPY; POLYMYOSITIS; PRIORITY JOURNAL; PYELONEPHRITIS;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOSITIS; REGISTRIES; TREATMENT OUTCOME;

EID: 82355170762     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker305     Document Type: Article

References (49)

1. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003;362:971-82.
2. Bronner IM, van der Meulen MF, de Visser M et al. Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis 2006;65:1456-61.
3. Boswell JS, Costner MI. Leflunomide as adjuvant treatment of dermatomyositis. J Am Acad Dermatol 2008;58: 403-6.
4. Sangle VS, Sangle SR, D'Cruz DP. Leflunomide as a remission-maintaining therapy in difficult-to-treat dermatomyositis. Ann Rheum Dis 2008;67:723.
5. Vencovský J, Jarosová K, Machácek S et al. Cyclosporin A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000;29: 95-102.
6. Ochi S, Nanki T, Takada K et al. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. Clin Exp Rheumatol 2005;23:707-10.
7. Yamasaki Y, Yamada H, Yamasaki M et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology 2007;46:124-30.
8. Bunch TW, Worthington JW, Combs JJ et al. Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med 1980;92:365-9.
9. Miller J, Walsh Y, Saminaden S et al. Randomized double blind trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy. J Neurol Sci 2002;199(Suppl. 1): S53.
10. Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology 2005;44:386-9.
11. Pisoni CN, Cuadrado MJ, Khamashta MA et al. Mycophenolate mofetil treatment in resistant myositis. Rheumatology 2007;46:516-8.
12. Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 2004;291:2367-75.
13. Arlet JB, Dimitri D, Pagnoux C et al. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord 2006;16: 334-6.
14. Efthimiou P, Schwartzman S, Kagen LJ. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 2006;65:1233-6.
15. Riley P, McCann LJ, Maillard SM et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology 2008;47:877-80.
16. Iannone F, Scioscia C, Falappone PC et al. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 2006;33:1802-4.
17. Dastmalchi M, Grundtman C, Alexanderson H et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008;67:1670-7.
18. Villalba L, Hicks JE, Adams EM et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 1998;41: 392-9.
19. Cohen SB, Emery P, Greenwald MW et al. REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
20. Seror R, Sordet C, Guillevin L et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis 2007;66:351-7.
21. Meijer J, Meiners P, Vissink A et al. Effective rituximab treatment in primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:960-8.
22. Gottenberg JE, Guillevin L, Lambotte O et al. Club Rhumatismes et Inflammation (CRI). Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005;64:913-20.
23. Terrier B, Amoura Z, Ravaud P et al. Club rhumatisme et inflammatoire (CRI). Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AIR registry. Arthritis Rheum 2010;62: 2458-66.
24. Stone JH, Merkel PA, Spiera R et al. RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363: 221-32.
25. Jones RB, Cohen Tervaert JW, Hauser T et al. European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-20.
26. Touma Z, Arayssi T, Kibbi L et al. Successful treatment of cardiac involvement in dermatomyositis with rituximab. Joint Bone Spine 2008;75:334-7.
27. Dinh HV, McCormack C, Hall S et al. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol 2007;56: 148-53.
28. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005;52:601-7.
29. Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007;143:763-7.
30. Sem M, Molberg O, Lund MB et al. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology 2009;48:968-71.
31. Cooper MA, Willingham DL, Brown DE et al. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 2007;56:3107-11.
32. Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol 2007;34:1864-8.
33. Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 2006;33:1021-6.
34. Vandenbroucke E, Grutters JC, Altenburg J et al. Rituximab in life threatening antisynthetase syndrome. Rheumatol Int 2009;29:1499-502.
35. Chiappetta N, Steier J, Gruber B. Rituximab in the treatment of refractory dermatomyositis. J Clin Rheumatol 2005;11:264-6.
36. Brulhart L, Waldburger JM, Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis 2006;65:974-5.
37. Tournadre A, Amarger S, Joly P et al. Polymyositis and pemphigus vulgaris in a patient: successful treatment with rituximab. Joint Bone Spine 2008;75:728-9.
38. Lambotte O, Kotb R, Maigne G et al. Efficacy of rituximab in refractory polymyositis. J Rheumatol 2005;32:1369-70.
39. Pavy S, Rigolet A, Rozenberg S et al. Efficacité du rituximab pour le traitement de myosites à anticorps anti-Jo1 en rechute [abstract]. Rev du Rhum 2007;74: 1203.
40. Pavy S, Rigolet A, Jacozone-Levêque C et al. Efficacité du rituximab pour le traitement de myosites à anticorps anti-SRP réfractaires à la corticothérapie [abstract]. Rev du Rhum 2007;74:1202.
41. Sultan SM, Ng KP, Edwards JC et al. Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy. Clin Exp Rheumatol 2008;26:887-93.
42. Feist E, Dörner T, Sörensen H et al. Longlasting remissions after treatment with rituximab for autoimmune myositis. J Rheumatol 2008;35:1230-2.
43. Whelan BR, Isenberg DA. Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion. Rheumatology 2009;48:594-5.
44. Arlet JB, Dimitri D, Pagnoux C et al. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord 2006;16: 334-6.
45. Hoogendijk JE, Amato AA, Lecky BR et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004;14:337-45.
46. Kendall FP, McCreary EK, Provance PG. Muscles: testing and function. 4th edn. Baltimore: Williams and Wilkins, 1993.
47. András C, Ponyi A, Constantin T et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 2008;35:438-44.
48. Garypidou V, Perifanis V, Tziomalos K et al. Cardiac toxicity during rituximab administration. Leuk Lymphoma 2004;45:203-4.
49. National Institute of Arthritis and Muskuloskeletal and Skin Diseases (NIAMS). Rituximab for the treatment of refractory adult and juvenile dermatomyositis (DM) and adult polymyositis (PM). www.clinicaltrial.gov NCT00106184 (28 July 2010, date last accessed).